Hasler-Rapacz J, Kempen H J, Princen H M, Kudchodkar B J, Lacko A, Rapacz J
Department of Genetics, University of Wisconsin, Madison 53706-1284, USA.
Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):137-43. doi: 10.1161/01.atv.16.1.137.
Familial hypercholesterolemia (FHC) in swine, which resembles human familial combined hyperlipidemia, is a complex lipid and lipoprotein disorder associated with the development of severe coronary lesions similar to those occurring in advanced human coronary disease. The disorder is characterized by elevated plasma total cholesterol (TC), triglycerides (TG), LDL-cholesterol (LDL-C), apolipoproteins (apo) B, C-III, and E, and by decreased levels of HDL-cholesterol (HDL-C), apoA-I, and lecithin:cholesterol acyltransferase (LCAT) activity. A dose-response study with simvastatin, a specific inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, was conducted in four treatment groups of FHC animals, exhibiting TC > or = 250 mg/dL. The animals were fed 0, 80, 200, or 400 mg simvastatin daily for 3 weeks. The measured serum parameters included the levels of TC, VLDL-C, LDL-C, HDL-C, TG, lathosterol, apoA-I, B, C-III, and E, as well as LCAT activity. Simvastatin at 200 mg/d significantly decreased the levels of TC (-25%), LDL-C (-27%), lathosterol (-40%), apoB (-22%), apoC-III (-37%), and apoE (-24%) and modestly decreased the levels of HDL-C (-12%) and apoA-I (-11%) (percent relative to the average pretreatment and posttreatment baseline values) but did not affect the levels of TG, VLDL-C, the lathosterol/TC ratio, or LCAT activity. The levels of TC, LDL-C, apoB, and E were also lowered by simvastatin at 80 or 400 mg/d, but to a lesser extent than at 200 mg/d, while the other parameters were not influenced at these doses. The simvastatin-induced decreases of LDL-C, HDL-C, and apoA-I, B, C-III, and E were significantly correlated among each other. These results show that the trend of responses in TC, LDL-C, apoB, apoC-III, and apoE to simvastatin in the FHC swine is similar to that observed in humans, although the drugs is less potent and efficacious in swine, while the results are different from those in humans with regard to the remaining parameters.
猪的家族性高胆固醇血症(FHC)类似于人类家族性混合性高脂血症,是一种复杂的脂质和脂蛋白紊乱疾病,与严重冠状动脉病变的发展有关,这些病变类似于晚期人类冠状动脉疾病中出现的病变。该疾病的特征是血浆总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、载脂蛋白(apo)B、C-III和E升高,以及高密度脂蛋白胆固醇(HDL-C)、apoA-I和卵磷脂胆固醇酰基转移酶(LCAT)活性水平降低。在四组FHC动物(TC≥250mg/dL)中进行了一项使用辛伐他汀(一种3-羟基-3-甲基戊二酰辅酶A(HMG-CoA)还原酶的特异性抑制剂)的剂量反应研究。这些动物每天分别喂食0、80、200或400mg辛伐他汀,持续3周。测量的血清参数包括TC、极低密度脂蛋白胆固醇(VLDL-C)、LDL-C、HDL-C、TG、羊毛甾醇、apoA-I、B、C-III和E的水平,以及LCAT活性。200mg/d的辛伐他汀显著降低了TC(-25%)、LDL-C(-27%)、羊毛甾醇(-40%)、apoB(-22%)、apoC-III(-37%)和apoE(-24%)的水平,并适度降低了HDL-C(-12%)和apoA-I(-11%)(相对于治疗前和治疗后平均基线值的百分比),但未影响TG、VLDL-C、羊毛甾醇/TC比值或LCAT活性。80或400mg/d的辛伐他汀也降低了TC、LDL-C、apoB和E的水平,但程度低于200mg/d,而在这些剂量下其他参数未受影响。辛伐他汀引起的LDL-C、HDL-C以及apoA-I、B、C-III和E的降低彼此之间显著相关。这些结果表明,FHC猪中TC、LDL-C、apoB、apoC-III和apoE对辛伐他汀的反应趋势与在人类中观察到的相似,尽管该药物在猪中的效力和疗效较低,而在其余参数方面结果与人类不同。